Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

Vertex Pharmaceuticals (VRTX) announced several updates on the company’s type 1 diabetes portfolio. Vertex has completed enrollment and dosing ...

Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.

as well as VX-880 and VX-264 for type 1 diabetes. The outcomes of these pipeline programs could significantly impact Vertex’s long-term growth prospects and market valuation. Vertex’s pricing strategy ...

as well as VX-880 and VX-264 for type 1 diabetes. The outcomes of these pipeline programs could significantly impact Vertex’s long-term growth prospects and market valuation. Vertex’s pricing ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

The non-profit Institute for Clinical and Economic Review has issued a lukewarm final evidence report on Vertex ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

VX-880 (formerly known as STx-02) derives from Vertex’ near $1 billion acquisition of Semma in 2019, and has started enrolling patients in a phase 1/2 study in the US. The therapy takes the form ...

2-Year U.S. Treasury Note Continuous Contract $103.535 0.047 0.05% 5-Year U.S. Treasury Note Continuous Contract $108.070 0.148 0.14% 10-Year U.S. Treasury Note Continuous Contract $111.297 0.297 ...